Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Tech’s tectonic plates are shifting — will Twitter, Meta and the other giants survive?

Amid job losses and tumbling share prices, all the platforms once thought too big to fail are now fighting to stay relevant. From Twitter to Meta, change is afoot, says John Arlidge

Evening Standard

1 No-Brainer Stock to Buy That Could Help You Retire Earlier

Biopharma giant AbbVie (ABBV) is well-placed to gain from its drug pipeline, recent drug approvals, and strategic acquisitions. Given its strong fundamentals, discounted valuation, high profitability, reliable dividends, and favorable analyst estimates, investing in this stock could help you retire earlier. Read more.

StockNews.com

Walmart offers to pay $3.1 billion to settle opioid lawsuits

The retail giant becomes the latest major player in the drug industry to announce a plan to settle lawsuits filed by state and local governments over the toll of opioids sold at its pharmacies.

WEKU

From analysis to the latest developments in health,
read the most diverse news in one place.

Walmart reaches $3.1 billion deal to settle opioid lawsuits

Walmart said that the proposed framework "does not include any admission of liability."

Axios

Female-led African health startups press on despite funding lags

Industry stakeholders say there has to be an intentional shift in investment strategy in the male-dominated field.

Al Jazeera

California programs are waiting weeks for free Narcan to prevent overdose deaths

LOS ANGELES — After losing her son Luke to an overdose, Sheila Scott has been trying to get "revenge on death," she said.

Los Angeles Times

For some COVID patients, 'Paxlovid rebound' has nothing to do with Paxlovid

This is a story about a COVID-19 medication, a nasty trick the coronavirus sometimes plays on its victims, and how the two became a pandemic couple called "Paxlovid rebound."

Los Angeles Times

Read news from The Economist, FT, and more,
with one subscription

Walmart latest pharmacy chain to propose opioid settlement

State attorneys general say Walmart has agreed to pay $3.1 billion to settle lawsuits nationwide over the impact of the prescriptions its pharmacies filled for powerful prescription opioid painkillers

The Independent UK

Nine Covid symptoms affecting the fully vaccinated — and signs you may have it

Fainting and fatigue may signal onset of variant, experts say

The Independent UK

Adderall shortage puts U.S. on brink of public health crisis

A rise in demand for Adderall has triggered a shortage of the drug.

Axios

Commentary: Don’t let Adderall scarcity trigger a repeat of the opioid epidemic

U.S. pharmacies are critically low on Adderall and its generic equivalents, leaving more than 26 million patients scrambling and competing for the pills since late summer. The scarcity is going to last for many more months because of supply chain problems as well as federal restrictions on manufacturers and imports.

Los Angeles Times

Twitter Prank Spurs Unexpected Scrutiny of Insulin Prices

A Twitter imposter cost a US pharmaceutical giant billions of dollars, but the viral prank triggered another unexpected crisis -- a new wave of scrutiny of the high cost of its insulin. Authentic-looking fake accounts proliferated last week after Twitter rolled out a paid verification service, the latest in a…

Asharq Al-Awsat

A New Omicron-Specific Booster Is Coming To Australia Next Month So Here’s What The Go Is

ATAGI gave the new Pfizer jab the all-clear on Tuesday.

Pedestrian.tv

Moderna’s bivalent shot boosts antibodies against latest omicron strains in trial

Moderna Inc.’s booster shot of its bivalent vaccine sharply increased antibody levels against recent COVID-19 strains when compared to a fourth dose of its original immunization.

Tribune News Service

Get all your
news in one place.

100’s of premium titles.
One news app.

ABC News

Pfizer's new Omicron-specific COVID booster to be available in Australia from next month

Another bivalent COVID-19 vaccine will be available to eligible Australians as a third and fourth booster, as case numbers climb.

AAP

Experts rule out third COVID booster shot

Despite a spike in COVID-19 cases, the country's leading vaccine advisory body says Australians don't yet need a fifth dose of vaccine.

Chronicle Live

Staff at Consett chemical manufacturing company to strike in row over pay

Workers are set to strike for five days as they call for higher wages during the cost of living crisis

Salon

The COVID "Franken-virus" threat

A hybrid "Deltacron" strain could overtake BQ.1.1 as the most prevalent COVID strain. Here's what that would mean

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Reunion Neuroscience Presents Q2 2023 Financial Results & Pipeline Update

Psychedelics biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) reported its business update and fiscal results for the second quarter ended September 30, 2022.

The Conversation

Unregulated 'innovation': India’s medicine problem

If India is the pharmacy of the world, it’s not doing a good job of providing safe products. A large number of children in the Gambia have recently died after ingesting cough syrup made in India. And in 2019, 11 children in India’s Jammu region died the same way. The…

StockNews.com

Is Gilead Sciences Still a Buy Post COVID-19?

Gilead Sciences’ (GILD) popular covid product Veklury (Remdisivir) witnessed declining sales in the post-pandemic era. However, the company’s top line, excluding Veklury, has seen steady growth. Moreover, despite ongoing market volatility, the stock has registered stable gains. So, let’s find out if GILD is still a buy in the post-covid…

Bristol Post

Bristol CBD company Amma Life promotes 'nature's gift' for wellness

It was one of the first CBD companies in the UK almost 10 years ago

Benzinga

Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday

U.S. stocks traded mixed, with the Nasdaq gaining more than 50 points on Monday. Here are some big stocks recording losses in today’s session.

Benzinga

Zynerba Pharmaceuticals R&D Expenses For Q3 Reach $5M, Here Are The Details

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), released financial results for the third quarter ended September 30, 2022. Q3 2022 Financial Highlights

The Guardian - UK

Disappointment after potential Alzheimer’s drug fails Roche trial

Swiss pharmaceutical firm carried out two identical phase 3 trials of gantenerumab, with about 1,000 volunteers in each

1 … 99 100 101 102

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations